Jupiter Neurosciences
CompanyUnited States
Jupiter Neurosciences develops one asset, in phase 2 (JOTROL in Parkinson's disease). Mostly small molecule acting on Oxidative stress and ROS signalling and inflammation; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 0
- Trials
- 1
- Signal
Pipeline
1Bioavailability-enhanced resveratrol formulation intended to reduce oxidative stress and neuroinflammation.
Phase 2, Small molecule, Oxidative stress and ROS signalling, Inflammation, Parkinson's disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Signals1
- Similar companies6